The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067) studies randomly assigned advanced NSCLC patients to either dacomitinib or erlotinib, while EGFR alteration examination was performed centrally on archived tumor samples. This evidence concerns the gene EGFR and non-small cell lung carcinoma.